Month: August 2024

PeopleVine continues to add Prestigious and Substantial Customers CHICAGO, Aug. 14, 2024 (GLOBE NEWSWIRE) — via IBN –Alliance Creative Group, Inc., (http://www.ACGX.us) (Stock Symbol OTC: ACGX) is pleased to announce the results of Operations for the Quarter Ending June 30, 2024. Revenues for the Quarter ending June 30, 2024 (“Q2 2024”) were $159,617 Gross Profits for the Quarter ending June 30, 2024 (“Q2 2024”) were $159,617 Net Income for the Quarter ending June 30, 2024 (“Q2 2024”) were $78,843. The total assets on the Balance Sheet for the Alliance Creative Group as of 6/30/24 were $4,601,150. The total outstanding common shares as of June 30, 2024 were 4,454,211 with 2,799,023 of those shares in the float – Same as the end of the last quarter. The Company ended the quarter with...

GLEN ALLEN, Va., Aug. 14, 2024 (GLOBE NEWSWIRE) — Adial Pharmaceuticals, Inc. (NASDAQ: ADIL) (“Adial” or the “Company”), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment and prevention of addiction and related disorders, today provided a business update and reported its financial results for the second quarter of 2024. Cary Claiborne, President and Chief Executive Officer of Adial, stated, “I’m proud of the important progress we have made during the second quarter of 2024 in advancing AD04, our lead investigational genetically targeted, serotonin-3 receptor antagonist, therapeutic agent for the treatment of Alcohol Use Disorder (AUD). In June we initiated a pharmacokinetics study of AD04. The final patient completed dosing in the second cohort in August, marking a significant milestone...

NEW YORK and TOKYO, Aug. 14, 2024 (GLOBE NEWSWIRE) — HeartCore Enterprises, Inc. (Nasdaq: HTCR) (“HeartCore” or “the Company”), a leading enterprise software and consulting services company based in Tokyo, reported financial results for the second quarter ended June 30, 2024. Second Quarter 2024 and Recent Operational HighlightsPartnered with INCUDATA Corp. to enhance corporate digital marketing strategies Announced Go IPO Client, BloomZ, began trading on the Nasdaq Stock Exchange Authorized second dividend payment of $0.02 per share Partnered with Hitachi Systems, Ltd. to offer combined package of HeartCore CMS and GRED Web Security Assessment Cloud Announced and hosted seminar on U.S. exchange listing strategies for Japanese companies with Akerman LLP and Gateway Group Sold a Go IPO Client Warrant for $9 million that will be...

Declared development candidate MGX-001 for the treatment of hemophilia A; plans to present 12-month NHP durability study data in September 2024 All Wave 1 Ionis collaboration programs advancing in lead optimization, unlocking potential for multiple development candidate nominations in 2025 Achieved milestone from partner Affini-T related to Metagenomi licensed technology Well capitalized with $299.9M in cash, cash equivalents and available-for-sale marketable securities at the end of Q2 2024; cash runway anticipated to support operating plans into 2027 EMERYVILLE, Calif., Aug. 14, 2024 (GLOBE NEWSWIRE) — Metagenomi, Inc. (Nasdaq: MGX) (Metagenomi), a precision genetic medicines company committed to developing curative therapeutics for patients using its proprietary, comprehensive metagenomics-derived gene editing toolbox, today...

PEMGARDA™ launched commercially in Q2 2024 with $2.3 million of net product revenue Notable acceleration of commercial results in early Q3 2024, with the anticipated peak fall/winter respiratory virus season approaching New commercial leadership with Chief Commercial Officer, Tim Lee, an experienced biopharmaceutical leader with demonstrated commercial success Achieved Medicare and Medicaid coverage, rapid growth in commercial coverage across national and regional plans, and strong growth in infusion center utilization Submitted Emergency Use Authorization (EUA) amendment request to U.S. FDA for PEMGARDA for the treatment of mild-to-moderate COVID-19 in certain immunocompromised patients Next generation molecule VYD2311 first-in-human clinical trial dosing scheduled to begin late August Ended Q2 2024 with cash and cash equivalents...

TORONTO, Aug. 14, 2024 (GLOBE NEWSWIRE) — Base Carbon Inc. (Cboe CA: BCBN) (OTCQX: BCBNF) with operations through its wholly-owned subsidiary, Base Carbon Capital Partners Corp. (“BCCPC”, together, with affiliates, “Base Carbon”, or the “Company”), is pleased to announce its second-quarter 2024 consolidated financial results and operational highlights. All financial references are denominated in U.S. dollars, unless otherwise noted. Company Highlights for the Three and Six Months Ended June 30, 2024:Continued generation and sale of carbon credits from the Company’s projects:Received payments of approximately $12.5 million during the quarter from carbon credit sales pursuant to the Vietnam project offtake arrangement. Subsequent to quarter-end, received a further payment of approximately $11.2 million from the sale of carbon...

-Q2, 2024 total revenues of $15.8 million grew +14% Y/Y and +7.7% Q/Q based on strong demand and output in the TrinScreen HIV business- -Point-of-Care product revenue of $4.6 million grew 119% Y/Y and +53% Q/Q- -Reiterating guidance to achieve approximately $20 million of annualized run-rate EBITDASO1 on annualized run-rate revenues of approximately $75 million by Q2, 2025- DUBLIN, Aug. 14, 2024 (GLOBE NEWSWIRE) — Trinity Biotech plc (Nasdaq: TRIB), a commercial stage biotechnology company focused on human diagnostics and diabetes management solutions, including wearable biosensors, today announced the Company’s results for the quarter ended June 30, 2024. Existing Business – Key Highlights Strong Revenue and Profitability ImprovementsStrong demand and output in TrinScreen HIV drove a 14.0% year-on-year revenue increase...